Physician profile
Ryan J Pradko
NPI 1841605888
$1,508.69
in general payments reported to CMS, 2019-2025
19 companies · $627 in 2025
The $627 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.50 · 2023: $151 · 2024: $709 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.20 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $232.84 | 2023-2025 | |
| Amgen INC. | $230.61 | 2023-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $208.26 | 2024-2025 | Veozah |
| Novo Nordisk INC | $178.58 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $173.48 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $61.49 | 2025 | Rexulti |
| Abbott Laboratories | $60.20 | 2023-2024 | Freestyle Libre 3 |
| Shield Therapeutics INC | $55.65 | 2024 | |
| Glaxosmithkline, LLC. | $46.60 | 2024-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $46.60 | 2025 | Mounjaro, Zepbound, Jardiance |
| Supernus Pharmaceuticals, INC. | $44.02 | 2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $34.27 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $27.53 | 2024-2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $22.50 | 2022 | |
| Inari Medical, INC. | $22.24 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $17.18 | 2025 | Vtama |
| Xeris Pharmaceuticals, INC. | $16.08 | 2024 | Gvoke Hypopen |
| Abbvie INC. | $15.32 | 2025 | |
| Dexcom, INC. | $15.24 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Pradko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.